Dendreon cancer news

Dendreon disclosed in its 2Q11 earnings that it expects to cut expenses to account for reduced near-term manufacturing needs, with the cuts including workforce reductions. Details were not disclosed on the extent of the cuts. The move comes after the company withdrew its full year revenue guidance as a result of lower-than-expected uptake of prostate cancer therapy Provenge sipuleucel-T, which FDA approved in April 2010. The autologous dendritic cells loaded with a fusion protein of prostatic acid phosphatase and an immunostimulatory cytokine is the company's only marketed product (see BioCentury, May 3, 2010). ...